Zenas BioPharma, Inc.
ZBIO
$19.16
-$1.24-6.08%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -366.89% | 1.39% | -55.55% | 36.18% | -36.26% |
| Total Depreciation and Amortization | -9.09% | -8.33% | -47.83% | -30.30% | -8.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,181.12% | 164.16% | -0.88% | 4.00% | 73.55% |
| Change in Net Operating Assets | 326.94% | -171.04% | 158.23% | -199.91% | 95.11% |
| Cash from Operations | -27.45% | 1.48% | -12.66% | 3.90% | -24.13% |
| Capital Expenditure | -- | -- | 100.00% | 75.68% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -333.16% | 135.66% | -30.18% | -2,256.08% | 86.32% |
| Cash from Investing | -333.16% | 135.66% | -30.16% | -2,209.88% | 86.04% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 15,877.02% | -45.41% | 1,639.39% | -98.44% | -97.30% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -113.03% | -- | -- | -- | -918.91% |
| Cash from Financing | 93.96% | 4,116.96% | 1,639.39% | -94.66% | -99.21% |
| Foreign Exchange rate Adjustments | -56.00% | 110.59% | -353.85% | -136.88% | 371.15% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -106.88% | 146.91% | -23.74% | -205.94% | -122.88% |